(XERS) Xeris Pharmaceuticals - Ratings and Ratios
Injectable, Glucagon, Diabetes, Hypoglycemia, Rescue
XERS EPS (Earnings per Share)
XERS Revenue
Description: XERS Xeris Pharmaceuticals August 27, 2025
Xeris Pharmaceuticals Inc (NASDAQ:XERS) is a US-based pharmaceutical company. As a trading analyst, its essential to understand the companys financial health, and the quarterly tax provision is a critical aspect of this. A tax provision represents the amount a company expects to pay in taxes for a given period. Analyzing this can provide insights into the companys profitability and potential future cash outlays.
XERS operates in the pharmaceuticals industry, a sector known for high R&D expenses and significant regulatory hurdles. Key economic drivers for XERS include the success of its product pipeline, particularly its diazoxide choline controlled-release (CCR) tablets for managing hypoglycemia in patients with congenital hyperinsulinism (CHI) and other conditions. The companys ability to secure favorable pricing, navigate reimbursement landscapes, and compete effectively against generics and branded competitors will be crucial.
To evaluate XERS potential, we should consider key performance indicators (KPIs) such as revenue growth, gross margin, R&D expenses as a percentage of revenue, and cash burn rate. The companys market capitalization of $1.188 billion USD and average trading volume of 2.66 million shares indicate a certain level of liquidity and investor interest. However, the absence of a P/E ratio and forward P/E ratio suggests that the company is currently unprofitable, which is not uncommon for biotech firms investing heavily in R&D.
The stocks technical indicators, such as its position above its 20-day, 50-day, and 200-day simple moving averages (SMA20, SMA50, SMA200), suggest a positive short-term trend. The Average True Range (ATR) indicates moderate volatility, and a beta of 0.86 implies that XERS is slightly less volatile than the overall market. Understanding these dynamics can help in assessing potential trading opportunities and risks.
To make informed trading decisions, its crucial to monitor XERS progress on its product pipeline, financial health, and market dynamics. This includes watching for announcements on clinical trial results, FDA approvals, and changes in market capitalization or trading volume. A hyper-rational approach demands a focus on verifiable data and a willingness to adjust analyses as new information becomes available.
XERS Stock Overview
| Market Cap in USD | 1,492m |
| Sub-Industry | Pharmaceuticals |
| IPO / Inception | 2018-06-21 |
XERS Stock Ratings
| Growth Rating | 81.5% |
| Fundamental | 42.4% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | 149% |
| Analyst Rating | 4.50 of 5 |
XERS Dividends
Currently no dividends paidXERS Growth Ratios
| Growth Correlation 3m | 90.4% |
| Growth Correlation 12m | 93.5% |
| Growth Correlation 5y | 17.1% |
| CAGR 5y | 86.15% |
| CAGR/Max DD 3y (Calmar Ratio) | 1.70 |
| CAGR/Mean DD 3y (Pain Ratio) | 4.99 |
| Sharpe Ratio 12m | 1.23 |
| Alpha | 183.03 |
| Beta | 0.904 |
| Volatility | 60.41% |
| Current Volume | 1853.2k |
| Average Volume 20d | 1846.4k |
| Stop Loss | 9.2 (-5.2%) |
| Signal | 0.77 |
Piotroski VR‑10 (Strict, 0-10) 2.5
| Net Income (-32.0m TTM) > 0 and > 6% of Revenue (6% = 14.8m TTM) |
| FCFTA -0.02 (>2.0%) and ΔFCFTA 10.08pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 36.75% (prev 52.29%; Δ -15.54pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.05 (>3.0%) and CFO -16.2m > Net Income -32.0m (YES >=105%, WARN >=100%) |
| Net Debt (197.9m) to EBITDA (7.39m) ratio: 26.77 <= 3.0 (WARN <= 3.5) |
| Current Ratio 1.95 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (156.0m) change vs 12m ago 5.14% (target <= -2.0% for YES) |
| Gross Margin 81.14% (prev 80.73%; Δ 0.40pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 73.83% (prev 54.69%; Δ 19.15pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -0.17 (EBITDA TTM 7.39m / Interest Expense TTM 30.2m) >= 6 (WARN >= 3) |
Altman Z'' -7.01
| (A) 0.27 = (Total Current Assets 185.6m - Total Current Liabilities 95.2m) / Total Assets 334.7m |
| (B) -2.04 = Retained Earnings (Balance) -683.0m / Total Assets 334.7m |
| warn (B) unusual magnitude: -2.04 — check mapping/units |
| (C) -0.02 = EBIT TTM -5.17m / Avg Total Assets 333.2m |
| (D) -1.93 = Book Value of Equity -683.0m / Total Liabilities 354.0m |
| Total Rating: -7.01 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 42.41
| 1. Piotroski 2.50pt = -2.50 |
| 2. FCF Yield -0.39% = -0.20 |
| 3. FCF Margin -2.70% = -1.01 |
| 4. Debt/Equity -13.32 = -2.50 |
| 5. Debt/Ebitda 26.77 = -2.50 |
| 6. ROIC - WACC (= -10.98)% = -12.50 |
| 7. RoE 113.9% = 2.50 |
| 8. Rev. Trend 96.05% = 7.20 |
| 9. EPS Trend 78.20% = 3.91 |
What is the price of XERS shares?
Over the past week, the price has changed by +4.19%, over one month by +16.73%, over three months by +74.46% and over the past year by +201.24%.
Is Xeris Pharmaceuticals a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of XERS is around 10.54 USD . This means that XERS is currently overvalued and has a potential downside of 8.66%.
Is XERS a buy, sell or hold?
- Strong Buy: 4
- Buy: 1
- Hold: 1
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the XERS price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 9 | -7.2% |
| Analysts Target Price | 9 | -7.2% |
| ValueRay Target Price | 11.8 | 21.1% |
XERS Fundamental Data Overview October 20, 2025
P/E Forward = 22.1729
P/S = 6.0647
P/B = 3.3354
Beta = 0.904
Revenue TTM = 246.0m USD
EBIT TTM = -5.17m USD
EBITDA TTM = 7.39m USD
Long Term Debt = 218.6m USD (from longTermDebt, last quarter)
Short Term Debt = 12.3m USD (from shortTermDebt, last quarter)
Debt = 257.2m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 197.9m USD (from netDebt column, last quarter)
Enterprise Value = 1.69b USD (1.49b + Debt 257.2m - CCE 59.3m)
Interest Coverage Ratio = -0.17 (Ebit TTM -5.17m / Interest Expense TTM 30.2m)
FCF Yield = -0.39% (FCF TTM -6.64m / Enterprise Value 1.69b)
FCF Margin = -2.70% (FCF TTM -6.64m / Revenue TTM 246.0m)
Net Margin = -13.01% (Net Income TTM -32.0m / Revenue TTM 246.0m)
Gross Margin = 81.14% ((Revenue TTM 246.0m - Cost of Revenue TTM 46.4m) / Revenue TTM)
Gross Margin QoQ = 79.58% (prev 85.48%)
Tobins Q-Ratio = 5.05 (Enterprise Value 1.69b / Total Assets 334.7m)
Interest Expense / Debt = 2.86% (Interest Expense 7.36m / Debt 257.2m)
Taxrate = -0.0% (0.0 / -1.93m)
NOPAT = -5.17m (EBIT -5.17m * (1 - -0.00%)) [loss with tax shield]
Current Ratio = 1.95 (Total Current Assets 185.6m / Total Current Liabilities 95.2m)
Debt / Equity = -13.32 (negative equity) (Debt 257.2m / totalStockholderEquity, last quarter -19.3m)
Debt / EBITDA = 26.77 (Net Debt 197.9m / EBITDA 7.39m)
Debt / FCF = -29.82 (negative FCF - burning cash) (Net Debt 197.9m / FCF TTM -6.64m)
Total Stockholder Equity = -28.1m (last 4 quarters mean from totalStockholderEquity)
RoA = -9.56% (Net Income -32.0m / Total Assets 334.7m)
RoE = 113.9% (negative equity) (Net Income TTM -32.0m / Total Stockholder Equity -28.1m)
RoCE = -2.71% (EBIT -5.17m / Capital Employed (Equity -28.1m + L.T.Debt 218.6m))
RoIC = -2.59% (negative operating profit) (NOPAT -5.17m / Invested Capital 199.9m)
WACC = 8.40% (E(1.49b)/V(1.75b) * Re(9.35%) + D(257.2m)/V(1.75b) * Rd(2.86%) * (1-Tc(-0.0)))
Discount Rate = 9.35% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 6.26%
Fair Price DCF = unknown (Cash Flow -6.64m)
EPS Correlation: 78.20 | EPS CAGR: 49.11% | SUE: -0.34 | # QB: 0
Revenue Correlation: 96.05 | Revenue CAGR: 37.63% | SUE: 2.95 | # QB: 2
Additional Sources for XERS Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle